Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events

(2010) V. Caruso et al.   BLOOD

Rituximab–lenalidomide–dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

(2010) Vadim Ivanov et al.   LEUKEMIA & LYMPHOMA

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH